Meeting
2011 ASCO Annual Meeting
Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies.
Authors
C. Kohne
Onkologie Klinikum Oldenburg, Oldenburg, Germany
C. Kohne , C. Bokemeyer , S. Heeger , U. Sartorius , P. Rougier , E. Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00125034 and NCT00154102
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3576)
Abstract #
3576
Poster Bd #
14H
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Safety and efficacy during first line with cetuximab in KRAS wild-type metastatic colorectal cancer (mCRC): Results of a large prospective multicenter cohort carried out by the premium French observational study.
First Author: Laurent Mineur
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz
Poster
2015 ASCO Annual Meeting
Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial.
First Author: Stefan Kasper
Poster
2011 ASCO Annual Meeting
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS mutated tumors in the randomized German AIO study KRK-0306.
First Author: S. Stintzing